NCT06463522View on ClinicalTrials.gov

Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes Therapy in Patients With Hepatocellular Carcinoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

July 1, 2025

Study Completion Date

July 1, 2026

Conditions
Hepatocellular Carcinoma
Interventions
PROCEDURE

Autologous Tumor-infiltrating Lymphocytes

Autologous Tumor-infiltrating Lymphocytes, 2.0\*10\^7/Kg, single intravenous infusion.

Trial Locations (1)

Unknown

RECRUITING

the Fifth Medical Center of PLA, Beijing

All Listed Sponsors
lead

Beijing 302 Hospital

OTHER